Additionally, TAK-981 is being investigated in combination with immunotherapy (avelumab) and anti-EGFR antibodies for solid tumors (NCT04065555), with a particular focus on its role in modulating the tumor microenvironment. This evidence concerns the gene EGFR and neoplasm.